CYTESSE Trademark

Trademark Overview


On Monday, November 7, 2016, a trademark application was filed for CYTESSE with the United States Patent and Trademark Office. The USPTO has given the CYTESSE trademark a serial number of 87229072. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 8, 2020. This trademark is owned by Allergan Sales, LLC. The CYTESSE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable...
cytesse

General Information


Serial Number87229072
Word MarkCYTESSE
Filing DateMonday, November 7, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 8, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 7, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, November 10, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Monday, June 8, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 8, 2020ABANDONMENT - NO USE STATEMENT FILED
Friday, November 1, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 31, 2019EXTENSION 5 GRANTED
Tuesday, October 29, 2019EXTENSION 5 FILED
Thursday, October 31, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, October 29, 2019TEAS EXTENSION RECEIVED
Thursday, March 14, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 12, 2019EXTENSION 4 GRANTED
Tuesday, March 12, 2019EXTENSION 4 FILED
Tuesday, March 12, 2019TEAS EXTENSION RECEIVED
Saturday, October 20, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 18, 2018EXTENSION 3 GRANTED
Thursday, October 18, 2018EXTENSION 3 FILED
Thursday, October 18, 2018TEAS EXTENSION RECEIVED
Wednesday, May 2, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 30, 2018EXTENSION 2 GRANTED
Monday, April 30, 2018EXTENSION 2 FILED
Monday, April 30, 2018TEAS EXTENSION RECEIVED
Tuesday, September 19, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 15, 2017EXTENSION 1 GRANTED
Friday, September 15, 2017EXTENSION 1 FILED
Friday, September 15, 2017TEAS EXTENSION RECEIVED
Tuesday, May 2, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 7, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 7, 2017PUBLISHED FOR OPPOSITION
Wednesday, February 15, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 12, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 23, 2016NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, December 23, 2016LETTER OF SUSPENSION E-MAILED
Friday, December 23, 2016SUSPENSION LETTER WRITTEN
Wednesday, December 21, 2016ASSIGNED TO EXAMINER
Thursday, November 10, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, November 10, 2016NEW APPLICATION ENTERED IN TRAM